Clinical study on camrelizumab combined with anlotinib and FOLFOX regimen in treatment of advanced liver cancer

Abstract

Objective To observe the clinical effect of Camrelizumab for injection combined with Anlotinib Hydrochloride Capsules and FOLFOX regimen in treatment of advanced liver cancer. Methods Patients (126 cases) with advanced liver cancer in the Second Affiliated Hospital of Hainan Medical University and the First Affiliated Hospital of Hainan Medical University from January 2018 to December 2015 were randomly divided into control and treatment groups, and each group had 63 cases. Patients in two groups were given FOLFOX regimen: On the first day, oxaliplatin for injection, 85 mg/m2 added into 5% glucose injection 250 mL, was injected intravenously for 2 h. On the first and second day, Calcium Folinate for injection was injected intravenously for 2 h, 200 mg/m2 added into 5% glucose injection 250 mL. On the first and second day, Fluorouracil Injection was injected intravenously 400 mg/m2, while continuous intravenous drip of 600 mg/m2 for 22 h. After 14 d of treatment, it was suspended for 1 week. Patients in the control group were po administered with Anlotinib Hydrochloride Capsules before breakfast on the basis of FOLFOX regimen, 12 mg/time, once daily. The drug was taken continuously for 2 weeks, and stopped for 1 week. Patients in the treatment group were iv administered with Camrelizumab for injection on the basis of the control group, 3 mg/kg, and FOLFOX scheme shall be carried out after an interval of ≥ 30 min, once every 3 weeks. A cycle had 21 d, and patients in two groups were treated for 2 cycles. After treatment, the clinical efficacies were evaluated, and the serum levels of biochemical indexes and serological tumor markers in two groups were compared. Results After treatment, the DCR in the treatment group was significantly higher than that in the control group (P < 0.05), but there was no significant difference in the ORR between two groups. After treatment, the serum levels of ALT, AST, TBIL, and PT were significantly decreased, but the level of ALB were significantly increased (P < 0.05). The serum levels of ALT, AST, TBIL, and PT in the treatment group were lower than those in the control group, but the level of ALB was higher than those in the control group (P < 0.05). After treatment, the serum levels of AFU, AFP, CEA, and CA199 in two groups were significantly decreased (P < 0.05), and the serum levels of AFU, AFP, CEA, and CA199 in the treatment group were lower than those in the treatment group (P < 0.05). Conclusion Camrelizumab for injection combined with Anlotinib Hydrochloride Capsules and FOLFOX regimen has clinical curative effect in treatment of advanced liver cancer, can improve the disease control rate, biochemical indexes, and serum tumor markers, with good safety.